These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 36497475)

  • 1. Cytokines and Lymphoid Populations as Potential Biomarkers in Locally and Borderline Pancreatic Adenocarcinoma.
    González-Borja I; Viúdez A; Alors-Pérez E; Goñi S; Amat I; Ghanem I; Pazo-Cid R; Feliu J; Alonso L; López C; Arrazubi V; Gallego J; Pérez-Sanz J; Hernández-García I; Vera R; Castaño JP; Fernández-Irigoyen J
    Cancers (Basel); 2022 Dec; 14(23):. PubMed ID: 36497475
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neoadjuvant plus adjuvant or only adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer - the NEONAX trial (AIO-PAK-0313), a prospective, randomized, controlled, phase II study of the AIO pancreatic cancer group.
    Ettrich TJ; Berger AW; Perkhofer L; Daum S; König A; Dickhut A; Wittel U; Wille K; Geissler M; Algül H; Gallmeier E; Atzpodien J; Kornmann M; Muche R; Prasnikar N; Tannapfel A; Reinacher-Schick A; Uhl W; Seufferlein T
    BMC Cancer; 2018 Dec; 18(1):1298. PubMed ID: 30594153
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical characteristics and blood/serum bound prognostic biomarkers in advanced pancreatic cancer treated with gemcitabine and nab-paclitaxel.
    Blomstrand H; Green H; Fredrikson M; Gränsmark E; Björnsson B; Elander NO
    BMC Cancer; 2020 Oct; 20(1):950. PubMed ID: 33008332
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune cell infiltrates as prognostic biomarkers in pancreatic ductal adenocarcinoma: a systematic review and meta-analysis.
    McGuigan AJ; Coleman HG; McCain RS; Kelly PJ; Johnston DI; Taylor MA; Turkington RC
    J Pathol Clin Res; 2021 Mar; 7(2):99-112. PubMed ID: 33481339
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Results of a Randomized Clinical Study of Gemcitabine Plus Nab-Paclitaxel Versus Gemcitabine Plus S-1 as Neoadjuvant Chemotherapy for Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma (RCT, CSGO-HBP-015).
    Yamada D; Kobayashi S; Takahashi H; Iwagami Y; Akita H; Asukai K; Shimizu J; Yamada T; Tanemura M; Yokoyama S; Tsujie M; Asaoka T; Takeda Y; Morimoto O; Tomokuni A; Doki Y; Eguchi H
    Ann Surg Oncol; 2024 Jul; 31(7):4621-4633. PubMed ID: 38546797
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preoperative treatment with mFOLFIRINOX or Gemcitabine/Nab-paclitaxel +/- isotoxic high-dose stereotactic body Radiation Therapy (iHD-SBRT) for borderline resectable pancreatic adenocarcinoma (the STEREOPAC trial): study protocol for a randomised comparative multicenter phase II trial.
    Bouchart C; Navez J; Borbath I; Geboes K; Vandamme T; Closset J; Moretti L; Demetter P; Paesmans M; Van Laethem JL
    BMC Cancer; 2023 Sep; 23(1):891. PubMed ID: 37735634
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alterations in regulatory T cells and immune checkpoint molecules in pancreatic cancer patients receiving FOLFIRINOX or gemcitabine plus nab-paclitaxel.
    Sams L; Kruger S; Heinemann V; Bararia D; Haebe S; Alig S; Haas M; Zhang D; Westphalen CB; Ormanns S; Metzger P; Werner J; Weigert O; von Bergwelt-Baildon M; Rataj F; Kobold S; Boeck S
    Clin Transl Oncol; 2021 Nov; 23(11):2394-2401. PubMed ID: 33876417
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multiparametric MRI for prediction of treatment response to neoadjuvant FOLFIRINOX therapy in borderline resectable or locally advanced pancreatic cancer.
    Kang JH; Lee SS; Kim JH; Byun JH; Kim HJ; Yoo C; Kim KP; Ryoo BY; Kim SC
    Eur Radiol; 2021 Feb; 31(2):864-874. PubMed ID: 32813104
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel for Neoadjuvant Treatment of Resectable and Borderline Resectable Pancreatic Head Adenocarcinoma.
    Dhir M; Zenati MS; Hamad A; Singhi AD; Bahary N; Hogg ME; Zeh HJ; Zureikat AH
    Ann Surg Oncol; 2018 Jul; 25(7):1896-1903. PubMed ID: 29761331
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcomes of Primary Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma.
    Maggino L; Malleo G; Marchegiani G; Viviani E; Nessi C; Ciprani D; Esposito A; Landoni L; Casetti L; Tuveri M; Paiella S; Casciani F; Sereni E; Binco A; Bonamini D; Secchettin E; Auriemma A; Merz V; Simionato F; Zecchetto C; D'Onofrio M; Melisi D; Bassi C; Salvia R
    JAMA Surg; 2019 Oct; 154(10):932-942. PubMed ID: 31339530
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomised phase 2 trial of nab-paclitaxel plus gemcitabine with or without capecitabine and cisplatin in locally advanced or borderline resectable pancreatic adenocarcinoma.
    Reni M; Zanon S; Balzano G; Passoni P; Pircher C; Chiaravalli M; Fugazza C; Ceraulo D; Nicoletti R; Arcidiacono PG; Macchini M; Peretti U; Castoldi R; Doglioni C; Falconi M; Partelli S; Gianni L
    Eur J Cancer; 2018 Oct; 102():95-102. PubMed ID: 30149366
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Deciphering CHFR Role in Pancreatic Ductal Adenocarcinoma.
    González-Borja I; Alors-Pérez E; Amat I; Alonso L; Viyuela-García C; Goñi S; Reyes JC; Ceballos-Chávez M; Hernández-García I; Sánchez-Frías ME; Santamaría E; Razquin S; Arjona-Sánchez Á; Arrazubi V; Pérez-Sanz J; Vera R; Fernández-Irigoyen J; Castaño JP; Viúdez A
    Front Med (Lausanne); 2021; 8():720128. PubMed ID: 34869418
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of neoadjuvant FOLFIRINOX versus gemcitabine plus nab-paclitaxel in borderline resectable/locally advanced pancreatic cancer patients.
    Ingram MA; Lauren BN; Pumpalova Y; Park J; Lim F; Bates SE; Kastrinos F; Manji GA; Kong CY; Hur C
    Cancer Rep (Hoboken); 2022 Sep; 5(9):e1565. PubMed ID: 35122419
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic value of circulating T-lymphocyte subsets in advanced pancreatic cancer patients treated with mFOLFIRINOX or gemcitabine.
    Tulyte S; Characiejus D; Matuzeviciene R; Janiulioniene A; Radzevicius M; Jasiunaite E; Zvirblis T; Sileikis A
    Int Immunopharmacol; 2023 Feb; 115():109722. PubMed ID: 37724957
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of a MUC5AC Antibody (NPC-1C) Administered With Second-Line Gemcitabine and Nab-Paclitaxel on the Survival of Patients With Advanced Pancreatic Ductal Adenocarcinoma: A Randomized Clinical Trial.
    Huffman BM; Basu Mallick A; Horick NK; Wang-Gillam A; Hosein PJ; Morse MA; Beg MS; Murphy JE; Mavroukakis S; Zaki A; Schlechter BL; Sanoff H; Manz C; Wolpin BM; Arlen P; Lacy J; Cleary JM
    JAMA Netw Open; 2023 Jan; 6(1):e2249720. PubMed ID: 36602796
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical Outcome and Treatment Sequences of Patients with Advanced Pancreatic Cancer Treated with Contemporary Chemotherapy Protocols.
    Roehrle J; Kasper S; Treckmann JW; Markus P; Schumacher B; Albers D; Wendling J; Ting S; Mende B; Maßmann M; Markus M; Virchow I; Rosery V; Laue K; Zaun G; Kostbade K; Pogorzelski M; Reissig TM; Liffers ST; Schmid K; Schildhaus HU; Schuler M; Siveke JT; Wiesweg M
    Oncol Res Treat; 2023; 46(4):140-150. PubMed ID: 36720216
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of gemcitabine plus oxaliplatin versus gemcitabine plus nab-paclitaxel as first-line chemotherapy for advanced pancreatic adenocarcinoma: A single-center retrospective analysis.
    Schlick K; Gantschnigg A; Seymer A; Huemer F; Greil R; Weiss L
    Cancer Med; 2023 Aug; 12(16):16997-17004. PubMed ID: 37537780
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum cytokine levels are associated with tumor progression during FOLFIRINOX chemotherapy and overall survival in pancreatic cancer patients.
    van der Sijde F; Dik WA; Mustafa DAM; Vietsch EE; Besselink MG; Debets R; Koerkamp BG; Haberkorn BCM; Homs MYV; Janssen QP; Luelmo SAC; Mekenkamp LJM; Oostvogels AAM; Smits-Te Nijenhuis MAW; Wilmink JW; van Eijck CHJ;
    Front Immunol; 2022; 13():898498. PubMed ID: 36091056
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunomodulatory Effects of Endoscopic Ultrasound-Guided Thermal Ablation in Patients with Pancreatic Ductal Adenocarcinoma.
    Testoni SGG; Minici C; Benetti E; Clemente F; Boselli D; Sciorati C; De Monte L; Petrone MC; Enderle M; Linzenbold W; Protti MP; Manfredi A; De Cobelli F; Reni M; Falconi M; Capurso G; Arcidiacono PG; Della-Torre E
    Cancers (Basel); 2023 Jul; 15(14):. PubMed ID: 37509365
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Computed Tomography-Based Biomarker Outcomes in a Prospective Trial of Preoperative FOLFIRINOX and Chemoradiation for Borderline Resectable Pancreatic Cancer.
    Koay EJ; Katz MHG; Wang H; Wang X; Prakash L; Javle M; Shroff R; Fogelman D; Avila S; Zaid M; Elganainy D; Lee Y; Crane CH; Krishnan S; Das P; Fleming JB; Lee JE; Tamm EP; Bhosale P; Lee JH; Weston B; Maitra A; Wolff RA; Varadhachary GR
    JCO Precis Oncol; 2019; 3():. PubMed ID: 32914036
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.